Ligand Pharmaceuticals Incorporated (LGND) Q3 2018 Earnings Results

Ligand Pharmaceuticals Misses on EPS, Stock Up 5.04%

Despite missing EPS expectations, Ligand Pharmaceuticals saw a positive stock reaction, rising 5.04%. This increase may reflect investor confidence in the company's future potential, driven by ongoing partnerships and a strong pipeline. The lack of revenue data and guidance leaves some uncertainty, but management's optimistic tone could help maintain investor interest.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.32	N/A	-6.06%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains optimistic about the company's long-term prospects, focusing on strategic partnerships. They acknowledged the EPS miss but emphasized their commitment to innovation.

Management highlighted ongoing partnerships as a key driver for future growth.

They expressed confidence in their pipeline despite the EPS miss.

Ligand Pharmaceuticals Misses on EPS, Stock Up 5.04%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS, Stock Up 5.04%

Key numbers

Management commentary